Important information on health

[Guest guest]

Dear Friends,

 

Sai Ram. I am sharing with you an advance announcement received from a

professional friend, that will be of interest to all of us.

 

Regards

 

Swamy

 

Dawn Safrit <dawn

FlexNow ACCMER Media Advisory

swamyreviews

Thursday, 17 December, 2009, 1:03 AM

 

 

Dear S.V.Swamy Swarna, Freelance Journalist:

Exciting new research to be published in January is previewed

below:http://www3.interscience.wiley.com/journal/123208347/abstract. The

superior anti-inflammatory response found in the research subjects has

implications for relief of joint problems and pain associated with athletic

injuries as well as the wear and tear of aging. Moreover, the broad spectrum

reduction in inflammation goes beyond joints, cartilage and muscles. The

specific inflammatory markers affected also suggest benefits for heart health

and a wide range of serious health conditions. The product tested, FlexNow, is a

concentrated extract of shea fruit kernels, “nature’s steroids,†but

without harmful side effects.

*MEDIA ADVISORY*

New Joint Health Gold Standard Study to be Published by ACCMER in January 2010

In January, a double-blind, placebo-controlled study on inflammation will be

published by the Australian Center for Complementary Medicine Education and

Research (ACCMER).

The human trial, conducted by Phillip Cheras, Ph.D., showed an average 25

percent reduction in inflammation in subjects’ joints and a broad spectrum

anti-inflammatory response with benefits ranging from bones to cardiovascular

health. Actives in the study were administered high triterpeneshea nut extract

(FlexNow) over a 3-month period, which reduced critical inflammatory markers

including CTX-II, IL-6, TNF-alpha and CRP. Reduced CTX-II indicates cartilage

protection; less TNF-alpha translates as benefits for joints and muscles; IL-6

is associated with rheumatoid arthritis, osteoarthritis, diabetes and prostate

cancer; C-reactive protein is a marker for cardiovascular disease.

To arrange for an interview with Dr. Cheras in Australia, and clinicians in the

U.S., please contact Dean Draznin Communications 641-472-2257. Dr. Cheras is

adjunct associate professor with NatMed Research at Southern Cross University of

New South Wales.

###